The Latest SPAC News and Rumors: July 29, 2022

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Playtech no longer pursuing SPAC deal with Caliente and NewAmsterdam Pharma doses first patient in phase 3 trial

Playtech says no longer pursuing SPAC deal for unit of peer Caliente

UK gambling software provider Playtech said on Friday it had stopped pursuing talks with Caliente Interactive for the Mexican sports betting firm’s unit Caliplay to list publicly in the United States via a SPAC deal, citing weak capital market conditions.

Playtech currently receives a fee for the software and services it provides to Caliplay and has an option agreement with parent Caliente to buy 49% of the unit plus a right to buy new shares in the new vehicle, should Caliplay be bought out.

NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced the initiation of BROOKLYN, a pivotal Phase 3 clinical trial of obicetrapib in adult patients with a history of heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies. Obicetrapib is NewAmsterdam’s next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.

Frazier Lifesciences  (NASDAQ:FLAC) entered into a definitive agreement to combine with biotech firm NewAmsterdam Pharma Holding earlier this week on July 25, 2022.